E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/26/2005 in the Prospect News Biotech Daily.

Merrill Lynch keeps Millipore at neutral

Millipore Corp. was maintained by Merrill Lynch analyst J. Darryl Pardi at neutral after the company reported third-quarter earnings per share of $0.58, $0.03 above Merrill estimates, due primarily to wider margins, higher taxes and a higher diluted share count. Because of these factors, Merrill said it has lowered its fourth-quarter earnings per share estimate to $0.62 from $.0.64, though it maintains its 2006 earnings per share estimate at $2.80. Shares of the Billerica, Mass.-based biotechnology company were down $1.85, or 2.97%, at $60.48 on volume of 803,100 shares versus the three-month running average of 277,152 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.